The potential role of mitochondrial ATP synthase inhibitory factor 1 (IF1) in coronary heart disease: a literature review

Abstract

Cardiovascular disease (CVD) is the leading cause of death worldwide, and so the search for innovative and accurate biomarkers for guiding prevention, diagnosis, and treatment is a valuable clinical and economic endeavor. Due to a recent findings that the serum concentration of mitochondrial ATP synthase inhibitory factor 1 (IF1) is an independent prognostic factor in patients with coronary heart disease (CHD), we reviewed the role of this protein in myocardial ischemic preconditioning, its correlation to plasma high density lipoprotein (HDL), the predictive potential in patients with CHD, and its interplay with angiogenesis. IF1 has been positively correlated with plasma HDL-cholesterol, and is independently negatively associated with all-cause and CV mortality in patients with CHD. However, this conclusion is prevalently based on limited data, and more research is needed to draw definitive conclusions. IF1 seems to play an additional role in increasing cell vulnerability in oncologic diseases but may also function as modest inhibitor of angiogenesis in physiological conditions. It has been also explored that IF1 may rather act as a modulator of other molecules more significantly involved in angiogenesis, especially apolipoprotein A1 on which the largest effect could be observed. In conclusion, more research is needed to characterize the role of IF1 in patients with CHD.

The Effect of Chinese Medicine on Lipid and Glucose Metabolism in Acute Myocardial Infarction Through PPARγ Pathway

“…Adenosine triphosphate is considered as one of the most important indicators of assessing myocardial energy metabolism levels and EC reflects the general level of myocardial metabolism ( Maierean et al, 2017 ). As shown in Figure 1B , the peak plots of ATP, ADP, and AMP were effectively separated within 7.5 min.…”

Quantitative proteomics reveals the regulatory networks of circular RNA BTBD7_hsa_circ_0000563 in human coronary artery

“…Therefore, the recovery of mitochondrial function, including the respiratory activity and ATP‐producing capacity, has been considered as a primary therapeutic target for improving the prognosis of patients with CAD 19 . Results from a recent study have suggested that the serum concentration of mitochondrial ATP synthase inhibitory factor 1 is independently negatively associated with all‐cause and cardiovascular mortality in patients with CAD 20 . Another study suggested that ectopic ATP synthase on endothelial cells could be a potential and novel therapeutic target for CAD 21 …”

Neuroprotective Effect of a Novel ATP-Synthase Inhibitor Bedaquiline in Cerebral Ischemia-Reperfusion Injury

“…It has been suggested that ATPase plays a role in ischemic preconditioning in the heart [23] and the brain [24]. The main factor regulating ATPase activity during preconditioning is suggested to be a protein called mitochondrial F0F1 ATPase inhibitory factor 1 (IF1), which inhibits ATP hydrolysis by ATPase [25]. This protein seems to be expressed in response to hypoxia-inducible factor 1α (HIF-1α) in liver and brain cells [24,26].…”